Computer-aided design of vaccines

Biomeditsinskaya Khimiya

Volumn 49, Issue 4, 2003, Pages 309-332

  Sobolev, B N ^a   Poroikov, V V ^a   Olenina, L V ^a   Kolesanova, E F ^a   Archakov, A I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Artificial vaccines; Bioinformatics; Epitope prediction; Genomic data; Immunogenes; Informational resources

Indexed keywords

DNA; EPITOPE; VACCINE;

ANALYTIC METHOD; ANTIGENICITY; ARTICLE; COMPUTER AIDED DESIGN; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; GENE SEQUENCE; IMMUNOGENETICS; IMMUNOLOGY; MACROMOLECULE; MATHEMATICAL COMPUTING; MOLECULAR BIOLOGY; MOLECULE; NONHUMAN; PLASMID VECTOR; PREDICTION; PROTEOMICS; TIME; TRANSGENIC PLANT; VACCINE PRODUCTION; VIRUS VECTOR;

BACTERIA (MICROORGANISMS);

EID: 0346334786     PISSN: 23106905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Makela P.H. (2000) FEMS Microbiol. Rev., 24, 9-20.
2. Liljeqvist S., Stahl S.J. (1999) Biotechnol., 73, 1-33.
3. Ben-Yedidia T., Arnon R. (1997) Curr. Opin. Biotechnol., 8, 442-448.
4. Rappuoli R., Guidice G. del (1999) In: Vaccine. From Concept to Clinic, CRC Press LLC, Boca Raton, Boston, London, New York, Washington DC, pp.5-17.
5. Rappuoli R. (2000) Curr. Opin. Microbiol. 3, 445-450.
6. Andre F.E. (1990) Vaccine, 8 Suppl, S74-78.
7. Kao J.H., Chen D.S. (2002) Lancet Infect. Dis., 2, 395-403.
8. Parenti D. (1999) Conn. Med., 63, 570.
9. http://www.lymesite.com/vaccine.htm
10. Greco D., Salmaso S., Mastrantonio P., et al. (1966) N. Engl. J. Med., 334, 341-348.
11. Hyams KC. (2002) Curr. Gastroenterol. Rep., 4, 302-307.
12. Schultz A.M., Bradac J.A. (2001) AIDS, 15, (Suppl 5), S147-158.
13. Mooij P., Heeney J.L. (2001) Vaccine, 20, 304-321.
14. Migasena S, Heppner D.G., Kyle D.E., et al. (1997) Acta Trop., 67, 215-227.
15. Kandel R., Hartshorn KL. (2001) BioDrugs, 15, 303-323.
16. Jackson D., Cadman A., Zurcher T., Barclay W.S. (2002) J. Virol., 76, 11744-11747.
17. Jeon S.H., Ben-Yedidia T., Arnon R. (2002) Vaccine, 20, 2772-2780.
18. Agger E.M., Andersen P. (2002) Vaccine, 21, 7-14.
19. Doherty T.M., Olsen A.W., van Pinxteren L., Andersen P. (2002) Infect. Immun., 70, 3111-3121.
20. Gor D.O., Ding X., Li Q., Schreiber J.R., et al. (2002) Infect Immun., 70, 5589-5595.
21. Briles D.E., Hollingshead S.K., King J. et al. (2000) J. Infect. Dis., 182, 1694-1701.
22. Volpina O.M., Yarov A.V., Zhmak M.N. et al. (1996) Vaccine, 14, 1375-1380.
23. Grandi G. (2001) Trends Biotechnol., 19, 181-188.
24. Mount D.W. (2001) Bioinformatics: Sequence and Genome Analysis, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
25. Altschul S.F., Madden T.L., Schaffer A.A. et al. (1997) Nucleic Acids Res., 25, 3389-3402.
26. Bateman A., Birney E., Cerruti L. et al. (2002) Nucleic Acids Res., 30, 276-280.
27. Letunic I., Goodstadt L., Dickens N.J. et al. (2002) Nucleic Acids Res., 30, 242-244.
28. Falquet L., Pagni M., Bucher P. et al. (2002) Nucleic Acids Res., 30, 235-238.
29. Berthet F.X., Coche T., Vinals C. (2001) J. Biotechnol., 85, 213-226.
30. Nielsen H., Engelbrecht J., Brunak S., von Heijne G. (1997) Protein Eng., 10, 1-6.
31. Nielsen H, Brunak S, von Heijne G. (1999) Protein Eng., 12, 3-9.
32. Hayashi S., Wu H.C. (1990) J. Bioenerg. Biomembr., 22, 451-471.
33. Gavel Y., von Heijne G. (1990) Protein Eng., 3, 433-442.
34. Yan B., Zhang W., Ding J., Gao P.J. (1999) Protein Chem., 18, 511-521.
35. Ley P. van der, Heckels J.E., Virji M. et al. (1991) Infect. Immun., 59, 2963-2971.
36. Rost B. (1996) Methods Enzymol., 266, 525-539.
37. Kyte, J., Doolittle, R. (1982) J. Mol. Biol., 157, 105-132
38. Tettelin H., Saunders N.J., Heidelberg J. et al. (2000) Science, 287, 1809-1815.
39. Pizza M., Scarlato V., Masignani V. et al. (2000) Science, 287, 1816-1820.
40. Drabick J.J., Brandt B.L., Moran E.E. et al. (1999) Vaccine, 18, 160-172.
41. Katial R.K., Brandt BL, Moran E.E. et al. (2002) Infect. Immun., 70, 702-707.
42. Poolman J.T., Kriz-Kuzemenska P, Ashton F. et al. (1995) Clin. Diagn. Lab. Immunol., 2, 69-72.
43. Peterson J.D., Umayam L.A., Dickinson T. et al. (2001) Nucleic Acids Res., 29, 123-125.
44. Roccasecca R., Folgori A., Ercole B.B. et al. (2001) Int. Rev. Immunol., 20, 289-300.
45. Montgomery D.L. (2000) Brief Bioinform., 1, 289-296.
46. Louise R., Skjot V., Agger E.M., Andersen P. (2001) Scand. J. Infect. Dis., 33, 643-647.
47. Pennisi E. (1998) Science, 281, 324-325.
48. Wang R., Doolan D.L., Le T.P. et al. (1998) Science, 282, 476-480.
49. Hoffman S.L., Rogers W.O., Carucci D.J., Venter J.C. (1998) Nat. Med., 4, 1351-1353.
50. Stephens R.S. (2000) J. Infect. Dis., 181 (Suppl 3), S521-523.
51. Igietseme J.U., Black C.M., Caldwell H.D. (2002) BioDrugs., 16, 19-35.
52. Pellequer J.-L., Westhof E.., van Regenmortel M.H.V. (1994) In: Peptide antigens. A practical approach, IRL PRESS, Oxford University Press, Oxford, New York, Tokyo, pp.7-25.
53. Hopp, T.P., Woods, K.R. (1981) Proc. Natl. Acad. Sci. USA, 78, 3824-3828.
54. Nozaki Y, Tanford C. (1971) J. Biol. Chem., 246, 2211-2227.
55. Bull H.B., Breese K. (1974) Arch. Biochem. Biophys. 161, 665-670.
56. Parker J.M., Guo D., Hodges R.S. (1986) Biochemistry, 25, 5425-5432.
57. Karplus P.A., Schulz G.E. (1985) Naturwissenschaften, 72, S. 212.
58. Hopp T.P. (1984) Ann. Sclavo. Collana. Monogr., 1, 47-60.
59. Lee B., Richards F.M. (1971) J. Mol. Biol., 171, 479.
60. Welling G.W., Weijer W.J., van der Zee R., Welling-Wester S. (1985) FEBS Lett., 188, 215-218.
61. Chou P.Y., Fasman G.D. (1979) Biophys. J., 26, 367-373.
62. Odorico M., Pellequer J.-L. (2003) J. Mol. Recognit., 16, 20-22.
63. Carter J.M. (1994) Methods Mol. Biol., 36, 207-223.
64. Kolaskar AS, Kulkarni-Kale U. (1999) Virology, 261, 31-42.
65. Rammensee H., Bachmann J., Emmerich N.P. et al. (1999) Immunogenetics, 50, 213-219.
66. Albert E.D., Bodmer W.F., Bontrop R.E. et al. (2002) Tissue Antigens, 60, 407-464.
67. Dafforn T.R., Lesk A.M. (2000) In: Protein-Protein Recognition, Oxford University Press, Oxford, pp. 163-188.
68. Schonbach C., Koh J.L., Flower D.R. et al. (2002) Nucleic Acids Res., 30, 226-229.
69. Honeyman M.C., Brusic V., Stone N.L., Harrison L.C. (1998) Nat. Biotechnol., 16, 966-969.
70. Brusic V., Rudy G., Honeyman G. et al. (1998) Bioinformatics, 14, 121-130.
71. Nussbaum A.K., Kuttler C., Hadeler K.P. et al. (2001) Immunogenetics, 53, 87-94.
72. Stoltze L., Schirle M., Schwarz G. et al. (2000) Nat. Immunol., 1, 413-418.
73. Brusic V., van Endert P., Zeleznikow J. et al. (1999) In Silico Biol., 1, 109-121.
74. Blythe M.J., Doytchinova I.A., Flower D.R. (2002) Bioinformatics, 18, 434-439.
75. Jung G., Fleckenstein B., von der Mulbe F. et al. (2001) Biologicals, 29, 179-181.
76. Logean A, Rognan D. J (2002) Comput. Aided Mol. Des., 16, 229-243.
77. Rognan D., Lauemoller S.L., Holm A. et al. (1999) J. Med. Chem., 42, 4650-4658.
78. McAtee C.P., Lim M.Y., Fung K. et al. (1998) J. Chromatogr. B. Biomed. Sci. Appl., 714, 325-333.
79. Utt M., Nilsson I., Ljungh A., Wadstrom T. (2002) J. Immunol. Methods., 259, 1-10.
80. Bodmer J. (1996) Ciba Found Symp., 197, 233-253.
81. Jackson D.C., Purcell A.W., Fitzmaurice C.J. et al. (2002) Curr. Drug Targets., 3, 175-196.
82. Lairmore M.D., DiGeorge A.M., Conrad S.F. et al. (1995) J. Virol., 69, 6077-6089.
83. Panina-Bordignon P., Tan A., Termijtelen A. et al (1989) Eur. J. Immunol., 19, 2237-2242.
84. Contreras C.E., Ploton I.N., Siliciano R.F. et al. (1998) Infect. Immun., 66, 3579-3590.
85. Caro-Aguilar I., Rodriguez A., Calvo-Calle J.M. et al. (2002) Infect. Immun., 70, 3479-3492.
86. Panigada M., Sturniolo T., Besozzi G. et al. (2002) Infect. Immun., 70, 79-85.
87. Taneja V., David C.S. (1998) J Clin. Invest., 101, 921-926.
88. Taneja V., David C.S. (1999) Immunol. Rev., 169, 67-79.
89. Sarobe P, Pendleton C.D., Akatsuka T. et al. J. Clin. Invest., 102, 1239-1248.
90. Kato N., Ootsuyama Y., Tanaka T. et al. (1992) Virus Res., 22, 107-123.
91. Hoffman N.G. Seillier-Moiseiwitsch F., Ahn J. et al. (2002) J. Virol., 76, 3852-3864.
92. Farci P., Shimoda A., Wong D. et al. (1996) Proc. Natl. Acad Sci. USA, 93, 15394-15399.
93. Olenina L.V., Nikolaeva L.I., Sobolev B.N. et al. (2002) J. Viral. Hepat., 9, 174-182.
94. Patarroyo G., Franco L., Amador R. et al. (1992) Vaccine, 10, 175-178.
95. Tam J.P. (1994) In: Peptide Antigens. A Practical Approach. Oxford University Press, Oxford, New York, Tokyo, pp.83-115.
96. Gregersen J.P. (2001) Naturwissenschaften, 88, 504-513.
97. Streatfield S.J., Lane J.R., Brooks C.A. et al. (2003) Vaccine, 30, 812-815.
98. Haq T.A., Mason H.S., Clements J.D., Arntzen C.J. (1995) Science, 268, 714-716.
99. Mason H.S., Haq T.A., Clements J.D., Arntzen C.J. (1998) Vaccine, 16, 1336-1343.
100. Tacket C.O., Mason H.S., Losonsky G. et al. (1998) Nat. Med., 4, 607-609.
101. Arakawa T., Chong D.K., Langridge W.E. (1998) Nat. Biotechnol., 16, 292-297.
102. Richter L.J., Thanavala Y., Arntzen C.J., Mason H.S. (2000) Nat. Biotechnol., 18, 1167-1171.
103. Pharmaprojects 2002, PJB Publications Ltd.
104. Tackaberry E.S., Dudani A.K., Prior F. et al. (1999) Vaccine, 17, 3020-3029.
105. Clough J. (2002) Drug Discov. Today, 7, 886-887.
106. Bonetta L. (2002) Nat. Med., 8, 94.
107. Strober W., Kelsall B., March T.J. (1998) Clin. Immunol., 18, 1-30.
108. Gotsman I., Alper R., Klein A. et al. (2002) Cancer, 94, 406-414.
109. Tacket C.O., Mason H.S. (1999) Microbes Infect., 1, 777-783.
110. Kato-Maeda M., Bifani P.J., Kreiswirth B.N., Small P.M. (2001) J. Clin. Invest., 107, 533-537
111. Lollini P.L., Forni G. (2003) Trends Immunol., 24, 62-66.
112. Davis I.D., Jefford M., Parente P., Cebon J. (2003) J. Leukoc. Biol., 73, 3-29.
113. Meng W.S., Butterfield L.H. (2002) Pharm. Res., 19, 926-932.
114. Espinoza-Delgado I. (2002) Oncologist, 7 (Suppl. 3), 20-33.